External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Dec 9 / Roche and Genentech
Glofitamab▼ with gemcitabine and oxaliplatin is cost-effective versus rituximab with gemcitabine and oxaliplatin for US patients with relapsed/refractory diffuse large B-cell lymphoma who were not candidates for autologous stem cell transplant
STARGLO is a Phase III study of glofitamab▼ plus gemcitabine and oxaliplatin (GemOx; Glofit-GemOx) versus rituximab plus GemOx in autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. A cost-effectiveness analysis of these treatments, from a United States payer perspective, is presented.
Haematology Oncology Diffuse large B cell lymphoma ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 9 / Roche and Genentech
Glofitamab▼ in combination with rituximab plus ifosfamide, carboplatin, and etoposide shows favorable efficacy and manageable safety in patients with relapsed or refractory diffuse large B-cell lymphoma, eligible for stem cell transplant or chimeric antigen receptor T-cell therapy: results from a Phase Ib study
GO43693 is a Phase Ib study of glofitamab▼ in combination with rituximab plus ifosfamide, carboplatin, and etoposide in patients with relapsed or refractory diffuse large B-cell lymphoma, eligible for stem cell transplant or chimeric antigen receptor T-cell therapy. Preliminary efficacy and safety data from the GO43693 study are presented.
Haematology Oncology Diffuse large B cell lymphoma ASH-2024

Sign up or login to unlock the full suite of MEDICALLY features
Dec 9 / Roche and Genentech
Primary results of patient-reported outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab plus GemOx (R-GemOx) from the Phase III STARGLO study
STARGLO is a Phase III study of glofitamab▼ plus gemcitabine and oxaliplatin (GemOx; Glofit-GemOx) versus rituximab plus GemOx in autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma. This abstract presents patient-reported outcomes to capture the impact of treatment on health-related quality of life of patients from the STARGLO trial.
Haematology Oncology Diffuse large B cell lymphoma ASH-2024
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.